- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Evolent Health Receives $6.04 Average Price Target from Analysts
Stock rating is 'Moderate Buy' as company navigates value-based care transition
Mar. 28, 2026 at 10:40am
Got story updates? Submit your updates here. ›
Evolent Health, Inc. (NYSE:EVH), a healthcare technology and services company, has received a 'Moderate Buy' rating from 17 analysts covering the firm. The analysts have set an average 12-month price target of $6.04 for the stock, which is currently trading around $2.22.
Why it matters
Evolent Health's performance and outlook are closely watched as it helps health systems, physician groups, and health plans transition from traditional fee-for-service models to value-based care arrangements. The company's ability to execute on this shift will be crucial for its long-term success.
The details
The analysts' ratings and price targets reflect the challenges Evolent Health has faced recently, including a lowered price target from $10 to $5 by UBS Group and a downgrade from 'overweight' to 'sector weight' by KeyCorp. The company reported mixed quarterly results in February, with earnings per share beating estimates but revenue declining 27.5% year-over-year.
- Evolent Health reported Q4 2025 earnings on February 24, 2026.
- The company's stock opened at $2.22 per share on Friday, March 28, 2026.
The players
Evolent Health, Inc.
A U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs.
UBS Group
A global investment bank and financial services firm that lowered its price target for Evolent Health from $10 to $5.
KeyCorp
A major U.S. bank that downgraded Evolent Health from 'overweight' to 'sector weight' rating.
What’s next
Evolent Health will need to demonstrate continued progress in helping its clients transition to value-based care models in order to regain investor confidence and meet analysts' expectations.
The takeaway
As the healthcare industry shifts towards value-based reimbursement, companies like Evolent Health that provide the technology and services to enable this transition will play a critical role. However, Evolent faces near-term headwinds as it navigates this transformation, requiring close monitoring of its operational and financial performance.
